News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mayo Clinic's Dr. Robin Patel Named Principal Investigator For Curetis' Unyvero™ LRT Trial



5/14/2014 10:00:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that Robin Patel, M.D., Professor of Medicine and Microbiology at the Mayo Clinic in Rochester, Minn., has been named Lead Principal Investigator of the company’s Unyvero™ LRT Application FDA trial. The lower respiratory tract (LRT) application is designed to detect 17 pathogens and 22 antibiotic resistance gene markers of clinical importance in patients with suspected LRT infections. The Company also announced the addition of six new clinical trial sites in the last few quarters, expanding its clinical trial network to nine high-profile testing sites.

Dr. Patel, who chairs the Division of Clinical Microbiology and Mayo Clinic’s Bacteriology Laboratory and directs the Infectious Diseases Research Laboratory, is a specialist in the clinical detection and identification of bacteria, including the characterization of their antimicrobial resistance and susceptibility, particularly for biofilm-mediated infections. She succeeds Prof. Christine Ginocchio, M.D., formerly of North Shore-LIJ Health System Laboratories, who recently left North Shore-LIJ to assume a corporate position in the microbiology field.

To bolster enrollment and to capture potential geographical differences in pathogen and antibiotic resistance gene distribution, Curetis has also expanded its clinical trial network from three to nine testing sites over the past couple of quarters.

Participating trial centers testing at least 2,000 prospective lower respiratory tract samples include:

David Geffen School of Medicine at UCLA (Los Angeles, Calif.)
Johns Hopkins University School of Medicine (Baltimore, Md.)
Northwestern Memorial Hospital (Chicago, Ill.)
Mayo Clinic (Rochester, Minn.)
North Shore-LIJ Health System Laboratories (Lake Success, N.Y.)
University of Rochester Medical Center (Rochester, N.Y.)
Weis Research Center/Geisinger Health System (Danville, Penn.)
University of Washington Medical Center (Seattle, Wash.)
William Beaumont Hospital (Royal Oak, Mich.)

Disclaimer CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero™ technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero™ product which may be sold at some future point in time in the U.S. have not yet been established.

About the Unyvero™ System

The CE-marked Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result. It is marketed in Europe, Russia, the Middle East and various other non-European countries. In the U.S., Curetis is running a prospective multi-center clinical trial aimed at achieving FDA clearance registered under http://www.clinicaltrials.gov/ NCT01922024. The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure. Thereby, clinically relevant information is available within about four hours to support an informed therapy decision as early as possible. The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. The second CE-marked application, the Unyvero™ i60 ITI cartridge for implant & tissue infections, is also commercially available in Europe. Cartridges for additional indications are in various stages of development and preparation.

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques. To date, Curetis has raised total funds of over €49.1 million (~ USD 65 million). The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical, Sanofi Pasteur and Cempra Inc. as well as several international distribution agreements covering more than 20 countries.

Contact Curetis AG Max-Eyth-Str. 42 71088 Holzgerlingen, Germany Tel. +49 7031 49195-10 pr(at)curetis.com www.curetis.com International Media Inquiries akampion Dr. Ludger Wess / Ines-Regina Buth Managing Partners info(at)akampion.com Tel. +49 40 88 16 59 64 Tel. +49 30 23 63 27 68 U.S. Media Inquiries The Ruth Group Melanie Sollid-Penton msollid(at)theruthgroup.com Tel. +1 646 536 7023

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES